VasoDynamics develops patient-friendly, cost-effective therapies that prevent severe side effects from anticancer treatments, such as oral mucositis, dermatitis, and chemotherapy-induced alopecia. Their patented formulations enhance treatment tolerance and improve the quality of life for cancer patients while offering potential savings for healthcare payers.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatments, while effective at combating the disease, often induce severe side effects such as oral mucositis, dermatitis, and chemotherapy-induced alopecia, significantly impacting patients' quality of life. Current supportive care options may be inadequate or not patient-friendly, leading to reduced treatment adherence and potential dose reductions.
Solution
VasoDynamics develops patient-friendly therapies designed to prevent or mitigate the severe side effects associated with anticancer treatments. Their formulations aim to enhance treatment tolerance, allowing patients to better withstand chemotherapy and radiation. By focusing on preventing complications like oral mucositis, dermatitis, and hair loss, VasoDynamics seeks to improve the overall well-being and quality of life for cancer patients undergoing treatment. The company's technology is differentiated into three formulation platforms with product pipelines focused on protecting the skin, mucosa, and hair.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy or radiation therapy, as well as oncologists and healthcare providers seeking to minimize treatment-related side effects and improve patient outcomes.
Features
- NG11: Formulation for the prevention of radiation-induced oral mucositis (RIOM).
- NG12: Formulation for the prevention of radiation-induced dermatitis.
- NG13: Formulation for the prevention of chemotherapy-induced alopecia (hair loss).
- Affordable medicines that enable cancer patients to tolerate widely used anticancer therapies.